SOURCE: CZ BioMed Corp

September 08, 2011 10:21 ET

CZ BioMed Corp.: Progress in Pancreatic Cancer Cure Research -- PANRVLYSIN®

TAMPA, FL--(Marketwire - Sep 8, 2011) - CZ BioMed Corp. announced today they have successfully developed a new class of treatment in the fight against pancreatic cancer using oncolytic virotherapy. PANRVLYSIN® is a discovery of CZ BioMed Corp. PANRVLYSIN® is a novel, genetically engineered common cold-like virus that selectively kills only the pancreatic cancer cells, while leaving the normal and good cells within the body unharmed. Therefore, PANRVLYSIN® is vastly safer to use, when compared to traditional chemo- or radio-therapies of tumors, while also providing a much higher quality of life during the treatment period. This medical breakthrough will allow CZ BioMed to potentially help millions of people worldwide in their battle against pancreatic cancer.

PANRVLYSIN® was found to effectively kill a variety of pancreatic cancer cell in vitro (within test glass). Additionally, results have shown that PANRVLYSIN® induces tumor growth regression in vivo (within a living organism) as well. This new product has been well tolerated in all experimental mice to date, with PANRVLYSIN® specifically localizing to the tumor upon its local administration, and has not spread to other tissues or organs. Thus, our unique treatment is highly targeted and not harming areas of the body that are not currently infiltrated by the cancer.

During this process, the primary replication of oncolytic viruses within the cancer cells directly kills the targeted tumor cells. The resultant explosion of each cancer cell activates a cascade of anti-tumor immune responses, including a significant interferon release. These payloads act in concert with the primary oncolysis mechanism to eradicate the pancreatic cancer.

An estimated 43,140 patients have so far been diagnosed with pancreatic cancer in the United States in 2010, and about 36,800 have died from this disease. Pancreatic cancer is the fourth most common cause of cancer deaths, both in the United States and internationally. Pancreatic cancer often has a poor prognosis: for all stages combined, the 1- and 5-year relative survival rates are 25% and 6%, respectively; for local disease, the 5-year survival is approximately 20%, while the median survival for locally advanced and for metastatic disease, which collectively represent over 80% of individuals, is about 10 and 6 months, respectively. Therefore, a safe and effective treatment remains a critical need and is a tremendous opportunity for PANRVLYSIN®.

"We are very excited to reach this milestone today. Our hard work and dedication to cure pancreatic cancer has moved one step closer. This breakthrough will allow patients to recover faster, will not destroy the healthy cells and is the definitive next step towards the cure of this deadly disease. As we know, cancer does not discriminate. From notable figures such as Steve Jobs, to our relatives in the next room, we look to the future, for PANRVLYSIN® to save millions of lives and join the elite class of cancer drugs developed by: Roche; Eli Lilly; Amgen Inc.; Dendreon Corp.; Genzyme Corp.; AstraZeneca and many other respected companies in this relentless pursuit to eradicate cancer."
Calvin Cao, Founder/Chairman/CEO of CZ BioMed Corp.

As a result of this milestone, CZ BioMed Corp. will now open aggressive discussions with all interested global bio-pharmacy leaders, for partnership arrangements and licensing of the technologies. Simultaneously, the company will begin IND (Investigational-New-Drug) filings with the United States FDA to initiate Phase 1 clinical trials. If your company is interested in licensing these technologies, please contact CZ BioMed Corp. at for further details.

About CZ BioMed Corp:

CZ BioMed Corp. is a privately held Biotechnology company based in Tampa, FL, focused on the discovery, development and commercialization of a new class of high-tech biological products for the treatment of a wide variety of human cancers. CZ BioMed products use novel oncolytic viruses that have been genetically engineered to selectively target tumor cells, but not kill normal healthy cells. The mission of CZ BioMed Corp. is rooted in the knowledge of our invention with the products we provide positively affecting the quality of patients lives. Since everything we do, no matter how small, impacts the end product and ultimately people's lives, we accept only the highest ethical and quality standards, both from ourselves and others.

For further information about CZ BioMed Corp. please visit:

Forward Looking Statements

This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and general economic risks and uncertainties.

Contact Information

    CZ BioMed Corp.
    Phone: 813-600-4088